FDA approval of ICOTYDE ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson highlights promising first-in-human Erda-iDRS results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson seeks FDA approval of IMAAVY® as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia
TREMFYA® long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
RYBREVANT FASPRO plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
